Related Experiment Video
Updated: May 9, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Preclinical research in treatment of pancreatic cancer
Evangelia Skoura1, Konstantinos N Syrigos, Muhammad Wasif Saif
1Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital. Athens, Greece. lskoura@yahoo.gr
Abstract:
Pancreatic adenocarcinoma is an aggressive type of malignancy and remains a treatment-refractory cancer. Because of the few treatment options, understanding of the molecular mechanisms is necessary, for new drugs be developed against molecular targets. Two of the novel, promising regimens against molecular targets, NVP-BEZ235 and MSK-777, were examined in three preclinical studies performed in human pancreatic cell lines and mouse models and presented in the 2013 ASCO Annual Meeting. Two of the studies evaluated the role of NVP-BEZ235, an oral phosphatidylinositol-3-kinase (PI3K) inhibitor, in pancreatic cancer treatment, alone and in combination with nab-paclitaxel (Abstract #e15007) or gemcitabine (Abstract #e15070). The third study presents the effectiveness of the novel cell division cycle 7 (Cdc7) kinase inhibitor, MSK-777 (Abstract #e15059). All studies demonstrated promising results and further investigation is ongoing.
Insights
Novel molecularly targeted drugs show promise for treating pancreatic cancer. Preclinical studies of NVP-BEZ235 (a PI3K inhibitor) and MSK-777 (a Cdc7 inhibitor) demonstrated encouraging outcomes in cell lines and mouse models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Pancreatic adenocarcinoma is an aggressive malignancy with limited treatment options.
- Understanding molecular mechanisms is crucial for developing targeted therapies.
- Novel molecularly targeted agents are under investigation.
Purpose of the Study:
- To evaluate the efficacy of NVP-BEZ235, a phosphatidylinositol-3-kinase (PI3K) inhibitor, in pancreatic cancer.
- To assess the effectiveness of MSK-777, a cell division cycle 7 (Cdc7) kinase inhibitor, in pancreatic cancer.
- To explore combination therapies involving NVP-BEZ235 with nab-paclitaxel or gemcitabine.
Main Methods:
- Preclinical studies using human pancreatic cancer cell lines.
- In vivo experiments utilizing mouse models of pancreatic cancer.
- Evaluation of NVP-BEZ235 as a single agent and in combination with chemotherapy.
- Assessment of MSK-777 efficacy.
Main Results:
- NVP-BEZ235 demonstrated efficacy in pancreatic cancer models.
- Combination of NVP-BEZ235 with nab-paclitaxel or gemcitabine showed promising results.
- MSK-777 exhibited effectiveness as a novel Cdc7 kinase inhibitor.
- All studies presented encouraging outcomes.
Conclusions:
- NVP-BEZ235 and MSK-777 represent promising novel therapeutic strategies for pancreatic cancer.
- Targeted inhibition of PI3K and Cdc7 pathways warrants further investigation.
- Combination therapies may enhance treatment efficacy in pancreatic adenocarcinoma.
